Mahesh Krishnan's most recent trade in Halozyme Therapeutics Inc. was a trade of 5,750 Option to Purchase Common Stock done . Disclosure was reported to the exchange on May 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | Mahesh Krishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,750 | 5,750 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Mahesh Krishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,165 | 10,666 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Mahesh Krishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 8,804 | 8,804 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Mahesh Krishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 6,501 | 6,501 (0%) | 0% | 0 | Common Stock |